Double-blind controlled trial of prostacyclin in cerebral infarction.
Thirty-two patients with acute cerebral infarction received either prostacyclin or placebo intermittently for 65 hours. Pulse and blood pressure were not altered by prostacyclin. After infusion there was no change in infarct volume or cerebral blood flow in either group. After normalisation for starting values, age and site of cerebral infarction there was a greater than 10% improvement in speech in the prostacyclin group, but minimal changes in neurological score or disability status. Age is related to neurological score at 14 days after stroke by decreasing improvement by 6.8% for each additional 10 years. This study has not been able to demonstrate that prostacyclin is effective in the treatment of ischaemic stroke, but due to the sample size the chance of proving this statistically (the power) was small. Similarly any conclusion that prostacyclin is not effective may be wrong because of the Type II error probability being high.
D000368:Aged; D002544:Cerebral Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002560:Cerebrovascular Circulation; D004311:Double-Blind Method; D011464:Epoprostenol / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications; D013064:Speech Disorders / Q000453:epidemiology
D011464:Epoprostenol